The FDA received an application for Nubeqa as a potential treatment option with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.
It is one of the common treatment options for prostate cancer and can be used in various stages of the disease, either alone or in combination with other treatments like surgery or hormone therapy.
May 25, 2022 — Men taking either of the two most common oral medications for advanced prostate cancer who had also undergone hormone therapy to treat their disease were at higher risk of serious ...